BTK and cancer: Previous studies have shown that DCs from BTK-deficient mice present a more mature phenotype, characterised by the expression of higher levels of activation markers and enhanced T cell stimulatory abilities in vitro and in vivo.15 Furthermore, our group has demonstrated that ibrutinib promotes DC activation and maturation, as well as T cell proliferation and augmented production of interferon (IFN)-γ.16,17 These findings suggest that ibrutinib could be effective in DC-based cancer therapeutics.